PIK3CA and breast cancer: Similarly, ~65% of eligible breast cancer patients (namely phosphatidylinositol 3-kinase alpha isoform (PIK3CA) mutant and hormone receptor positive) failed to respond to the PI3K inhibitor alpelisib (BYL-719) in a recent clinical trial14.